Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AIMMUNE THERAPEUTICS, INC.

(AIMT)
SummaryChartsNewsRatingsCompany 
Investment -
Trading
ESG Refinitiv -
Financials
Sales Growth
Growth rating is based on the evolution of the turnover of the company between the last year and the three coming years according to consensus estimates
-
Earnings Growth -
EBITDA / Sales -
Profitability
Profitability rating is based on net margin of the company for the current year and the next one according to consensus estimates
-
Finances
Finances rating is based on the evolution of the net debt of the company (debt or cash) and its Ebitda, compared to its revenue
-
Valuation
P/E ratio
Price Earnings Ratio rating compared the companyĺs current share price to its per-share earnings for the current fiscal year and the next one
-
EV / Sales
Valuation rating is based on the ratio between enterprise value and its turnover for the current fiscal year and the next one
-
Price to Book -
Price to Free Cash Flow -
Yield
"Yield" rating is based on the dividend relative to its share price
-
Momentum
Turnover review 12m
Revenue revisions (one year) rating is based on the evolution of revenue revisions of the company for the current fiscal year and the next one
Turnover review 4m
Revenue revisions (four months) rating is based on the evolution of revenue revisions of the company for the current fiscal year and the next one
Turnover review 7 days
Earnings revision 12m
EPS revisions (one year) rating is based on the evolution of EPS (earnings per share) revisions of the company for the current fiscal year and the next one
Earnings revision 4m
EPS revisions (four months) rating is based on the evolution of EPS (earnings per share) revisions of the company for the current fiscal year and the next one
Consensus
Analyst Opinion
Consensus rating is based on analyst recommendations
-
Potential Price Target
Potential rating is based on the average target price fixed by the consensus from Thomson Reuters
-
Price target revision 4m
Revision of opinion 4m -
Revision of opinion 12m -
Business Predictability
Analyst Coverage
Divergence of Estimates
Business Predictability rating is based on the dispersion of analysts' estimates on the evolution of the company business in the coming years (range estimates)
Divergence of analysts' opinions -
Divergence of Target Price -
Earnings quality
Earnings quality rating is based on quality of past earnings released by the company compared to analysts' estimates
Technical analysis
Short Term Timing
Short Term Timing rating is defined according to the positioning of the last closed trading price, within the area between the short term support and resistance on the basis of technical analysis in daily data
-
Middle Term Timing
Mid-Term Timing rating is defined according to the positioning of the last closed trading price, within the area between the mid-term support and resistance on the basis of technical analysis in daily data
-
Long Term Timing
Long Term Timing rating is defined according to the positioning of the last closed trading price, within the area between the long term support and resistance on the basis of technical analysis in daily data
-
RSI
RSI rating is based on the ranking of the security in the panel studied according to the mathematical indicator RSI 14 period
-
Bollinger Spread
Bollinger Bands rating is based on the ranking of the security in the panel studied according to the spread of the Bollinger bands
-
Unusual Volumes
Abnormal Volumes rating is based on the ranking of the security in the panel studied according to volume of the last session compared to an average session
-
Ratings chart - Surperformance
Sector Bio Therapeutic Drugs
1st jan.Capitalisation (M$)Investor Rating
AIMMUNE THERAPEUTICS, INC.0.00%2 268
-
GILEAD SCIENCES, INC.14.33%83 541
WUXI APPTEC CO., LTD.24.70%63 775
REGENERON PHARMACEUTICALS11.35%55 705
BIONTECH SE160.57%51 304
VERTEX PHARMACEUTICALS-20.52%48 628
BEIGENE, LTD.24.54%29 784
GENMAB A/S10.52%28 359
ARGENX SE10.41%16 252
HUALAN BIOLOGICAL ENGINEERI..-14.44%10 217
NEUROCRINE BIOSCIENCES, INC..4.87%9 504
DENALI THERAPEUTICS INC.-11.97%8 936
ARROWHEAD PHARMACEUTICALS, ..11.61%8 914
MIRATI THERAPEUTICS, INC.-24.17%8 568
REMEGEN CO., LTD.34.63%8 070
-
ACCELERON PHARMA INC.0.23%7 784
More Results